<DOC>
	<DOCNO>NCT01594203</DOCNO>
	<brief_summary>Soft Tissue Sarcoma ( STS ) rare tumor grow different area , example , 60 % limbs 20 % retroperitoneum ; frequently inoperable . Despite novel therapy advance case survival still short , approximately 12 month . Pazopanib oral angiogenesis inhibitor recently show promising drug advance pretreated STS . Functional image especially F18-FDG PET/CT good modality FDG avid tumor either pre- / post- treatment evaluation follow . Early detection treatment response therapy whole body FDG PET/CT allow change treatment early possible , tumor non-responsive serious side effect appear depletion body resource . The aim study investigate contribution FDG PET/CT assessment treatment response .</brief_summary>
	<brief_title>Contribution F18-FDG PET/CT Early Assessment Pazopanib Therapy Efficacy Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Patients advance Soft Tissue Sarcoma prior pazopanib treatment Other treatment FDG negative tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Soft Tissue Sarcoma</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>F18-FDG PET/CT</keyword>
</DOC>